BTG plc commences first clinical study of novel migraine treatment
BTG plc announced that BGC20-1531, a potential treatment for migraine headaches, has commenced clinical development. dosing has begun in a randomised, double-blind, placebo controlled phase I study, which will assess the safety, tolerability and pharmacokinetic profile of single rising doses of oral BGC20-1531 in healthy volunteers. The trial also incorporates a number of pharmacodynamic endpoints which may help to predict the efficacious dose range for future phase II studies in patients.
BTG licensed BGC20-1531 from Asterand plc (formerly Pharmagene plc) under an exclusive agreement in 2006. On reaching this clinical milestone, BTG has paid Asterand £250,000 as per the terms of the agreement.
Prostaglandin PGE2-induced cerebral vascular dilatation is thought to underlie migraine pain, particularly via activation of the EP4 receptor subtype. BGC20-1531 is an EP4 receptor antagonist that has been shown to competitively antagonise PGE2-induced vasodilatation of human middle cerebral and meningeal arteries in vitro, supporting its potential use as a treatment for migraine and other pain conditions. Furthermore, since EP4 receptors are discretely localised, the overall safety profile of EP4 receptor antagonists may be improved compared to triptans and NSAIDs.
Other news from the department research and development
